Forbes Sustainability Leaders Summit: Antheia’s CEO on Transforming Supply Chains

Antheia recently joined some of the industry’s most notable thought leaders at the prestigious Forbes Sustainability Leaders Summit, which gathered on September 20 in New York City to discuss insights, innovations, and visions for a more sustainable future. Antheia CEO and co-founder Dr. Christina Smolke had the honor of participating in a panel discussion that […]
Addressing the Drug Shortage Crisis: Transforming Pharma Supply Chains

Drug shortages in the U.S. have become an urgent issue over the last few years. So much so that in 2020, the Administration issued an Executive Order for the U.S. FDA to establish an Essential Medicines List of critical drugs that are deemed medically necessary, with the ultimate goal of identifying ways to protect and […]
Antheia at SynBioBeta: Leveraging Synthetic Biology to End Drug Shortages

Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. Antheia was a proud sponsor of this year’s event, and participated in two high impact talks designed to share our progress toward transforming pharmaceutical supply chains. In this first video, CEO […]
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines

Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains

We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic Chemistry in Pharma

Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Could synthetic biology solutions fix supply chain challenges?

An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes…
COVID-19 Vaccine Transforms Pharma Supply Chain Forever

The intricacies of the pharmaceutical supply chain may not have been in the mainstream news a few years ago, but recent events kicked this subject to front page news…
The Drug Supply Chain Is Broken. A New Breakthrough Paves The Way For On-Demand Plant-Based Medicine

When Covid hit and hospitals started reporting shortages of hydroxychloroquine and other medicines vital to patients with conditions like malaria, lupus, asthma, and COPD, it became clear that our drug supply chain was broken…
As Featured in STAT: The pharma supply chain is broken. Synthetic biology could fix it.

We started Antheia four years ago with a steadfast commitment to help build a more robust drug supply chain – one that delivers the right medicines to the right people, at the right time. In the era of COVID-19, this work is more important than ever before…